Pembrolizumab plus nab-paclitaxel active as salvage strategy in urothelial carcinoma
Given the efficacy and safety demonstrated, there may be a role going forward for the pembrolizumab/nab-paclitaxel combination in earlier disease stages.
Related Articles
Optimizing the use of next-generation sequencing assays in patients with urothelial carcinoma: recommendations by the 2023 San Raffaele Retreat panel
The application of precision medicine in clinical practice implies a thorough evaluation of actionable genomic alterations to streamline therapeutic decision making. Comprehensive genomic profiling of…
Master di I livello in Metodologia della Ricerca Clinica in Oncologia A.A. 23/24
Il Master di Primo Livello in Metodologia della Ricerca Clinica in Oncologia si propone di fornire ai partecipanti un’ adeguata e aggiornata preparazione teorica e…
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
Using preimmunotherapy stool samples collected from patients enrolled in the PURE-01 clinical trial, testing neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer, we identified some…
Genomic Profile and Clinical Outcomes of Penile Squamous Cell Carcinoma
This cohort study uses data from a nationwide database to characterize biomarker features and immune checkpoint inhibitor therapy outcomes associated with tumor mutational burden among…
ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence
Editor’s note: At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral…
Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
Breakthrough Therapy Designation for Novel Targeted Releasing System Based on Results from Ongoing Phase 2b SunRISe-1 Study
Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
Breakthrough Therapy Designation for Novel Targeted Releasing System Based on Results from Ongoing Phase 2b SunRISe-1 Study
Video Conferencing, Web Conferencing, Webinars, Screen Sharing
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile,…
Video Conferencing, Web Conferencing, Webinars, Screen Sharing
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile,…